We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life. High-throughput sequencing combined with real-time quantitative PCR will be used to comprehensively analyze the effects of different drugs on intestinal flora. The study has important guiding significance for the treatment of patients with IBS-D.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
the IBS symptom grade score
Timeframe: baseline
the quality of life score
Timeframe: baseline
the IBS symptom grade score
Timeframe: 2 weeks
the quality of life score
Timeframe: 2 weeks
the IBS symptom grade score
Timeframe: 12 weeks
the quality of life score
Timeframe: 12 weeks
16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota
Timeframe: 12 weeks
16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota
Timeframe: baseline
16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota
Timeframe: 2 weeks